Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1350289
European Journal of Endocrinology, Vol 135, Issue 3, 289-290
Copyright © 1996 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strasburger, C. J
Right arrow Articles by Kiess, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Strasburger, C. J
Right arrow Articles by Kiess, W.

Which route of growth hormone administration serves best? An invited commentary

Christian J Strasburger and Wieland Kiess

In the 1960s pharmacotherapy with pituitary-derived human growth hormone (GH) preparations was introduced into clinics for the treatment of children with severely impaired longitudinal bone growth (1). Initially, the generally accepted route of GH administration was deep intramuscular injections. It was not until the advent of recombinant growth hormone preparations in the 1980s that subcutaneous injection of GH proved to be at least equally effective and was propagated widely (2). The less traumatic subcutaneous injection then facilitated investigation of effectiveness as a function of number of injections per week. With respect to the promotion of longitudinal bone growth in children and adolescents, daily subcutaneous injection was shown to be more effective than administration of the same weekly dose by injection thrice weekly. Extrapolation of these findings promoted further studies in animals and humans that unanimously demonstrated the superior effectivity of continuous GH infusion as compared to administration of the same




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
G. Amato, G. Mazziotti, C. Di Somma, E. Lalli, G. De Felice, M. Conte, M. Rotondi, M. Pietrosante, G. Lombardi, A. Bellastella, et al.
Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3720 - 3725.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 European Society of Endocrinology.